É«»¨ÌÃ

Landing humans on the moon was just a dream when UCF was founded in 1963. But we dared to believe — developing the talent and inventing the technologies to make it reality. That same spirit still drives us today.

We are America’s Space University. And we celebrate UCF Space Week to honor our origin as we dare to build what’s next.

Where Global Leaders Unite to Forge the Future of Space

Whether it’s solving the world’s biggest problems or investigating the potential of novel discoveries, researchers at UCF are on the edge of scientific breakthroughs that aim to make an impact. Through the , student and faculty researchers condense their complex studies into bite-sized summaries so you can know how and why Knights plan to improve our world.

Name: Hansjorg Schwertz, M.D., Ph.D.

Position(s): Assistant professor of aerospace medicine; associate director for translational aerospace medicine research at the UCF Center for Aerospace and Extreme Environments Medicine (CASEEM)

Why are you interested in this research?
We study some of the smallest and most overlooked cells in the blood. Platelets are famous for stopping bleeding and forming blood clots, but they also talk to the immune system, help initiate and control inflammation, and play roles in conditions from infection to cancer. They are made by much larger cells in the bone marrow called megakaryocytes, which grow to an enormous size, pack themselves with the machinery for making proteins, and then extend long, branching arms from which thousands of platelets are released. What makes these cells especially intriguing to us is that platelets have no nucleus, yet they carry RNA blueprints and can finish processing them and build new proteins when they are activated. Understanding that hidden layer of platelet behavior has been the thread of our work for years.

During spaceflight, astronauts experience changes in blood clotting and immune regulation, and surprisingly little is known about what happens to megakaryocytes and platelets during a mission. That gap is what drew us in. I should be clear that this is not my research. It is our laboratory’s research, carried forward by many hands. We all run the experiments — technicians, students and collaborators — and often analyze the data through nights and weekends. The flight experiment on the International Space Station was simply the next question we got to ask together.

Who inspires you to conduct your research?
Family comes first: My wife and our daughters are my inspiration, my support and honestly my drivers. They push me and motivate me on the days when experiments fail, which is most days in research. I also want to show them, by example rather than words, that everything is possible if you are willing to work for it.

My mentors are the other half of the answer: Guy Zimmerman and Andy Weyrich at the University of Utah. They taught me how to do science, but more importantly how to treat people in science. Whatever our laboratory accomplishes rests on what they built, and the fact that our collaborations are still active says a lot about the kind of environment they created.

Furthermore, the students — whether I am talking to schoolchildren or university students — watching someone encounter the beauty of megakaryocytes and platelets for the first time is a reminder that the work matters beyond the laboratory.

And finally, within the MOON study itself, [University of Utah researchers and collaborators] Marina Tristao and Neal Tolley are the core team. We do the heavy lifting as a team, and none of this flies without them.

How does UCF empower you to do your research?
UCF has built something rare: a Division of Aerospace Medicine whose research goal is to understand how microgravity, radiation, and isolation affect the human body, and to turn that knowledge into better care for people in space and on Earth. As a tenure-track faculty member in the division and associate director for translational aerospace medicine research at the Center for Aerospace and Extreme Environments Medicine, I have an institutional home that is committed to exactly this kind of work. “Translational” is a word I care about: it means the path from a cell in a dish to an astronaut on orbit to a patient in a hospital should be short, and UCF is organized around making it short.

Just as important, UCF lets the collaboration continue. The MOON study began at the University of Utah and depends on partners there, on BioServe Space Technologies, whose hardware keeps our cells alive on orbit, and on the astronauts who perform the experiments themselves. Being able to keep that team together while growing new collaborations here is the real empowerment.

What major grants and honors have you earned to support your research?
The MOON study is supported by a NASA research award, and our laboratory has been fortunate to receive support over the years from the Volkswagen Foundation through a Lichtenberg Professorship, the German Research Foundation, the American Heart Association, and others. I say “our laboratory” deliberately because grants are written by teams and carried out by teams, and the funding belongs to the work, not to one person.

The honors I have received, including young investigator awards from the thrombosis and hemostasis community early in my career and fellowship in the occupational and aerospace medicine colleges more recently, mean the most as recognition of the mentors who trained me and the colleagues who did the work alongside me.

Why is this research important?
Because astronauts’ blood changes in space, and one of the more sobering possibilities is an increased risk of blood clots on long missions. We do not yet completely understand why, because no one has watched the cells that control clotting — the megakaryocytes and platelets — develop and function over the course of a spaceflight. Our experiment was the first to grow megakaryocytes on the International Space Station, and by comparing those cultures with blood samples taken from crew members before and after flight, we hope to connect what we see in a dish to what actually happens in a person.

Whatever comes of it will be a team accomplishment in the fullest sense: our laboratory on the ground, Marina, Neal, and myself running the experiments, collaborators in Utah, the engineers who built the hardware, and the astronauts who gave their time and their blood. If the findings help protect crews heading to the moon and Mars, that is the goal. And because the same cells misbehave in sepsis and clotting disorders here on Earth, there is a good chance the work helps patients who will never leave the ground.